Physician profile
Hanson Wright
NPI 1770229361
$4,693.76
in general payments reported to CMS, 2019-2025
27 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $142 · 2023: $1,181 · 2024: $2,109 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,204 · Education: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,203.79 |
| Education | $347.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $810.56 | 2022-2025 | |
| Lilly USA, LLC | $474.34 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $470.94 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $381.05 | 2022-2025 | Ilumya |
| Organogenesis INC. | $375.85 | 2024-2025 | Novachor, Via Matrix, Affinity |
| Ucb, INC. | $339.31 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $324.45 | 2023-2025 | Otezla, Otezla |
| Abbvie INC. | $268.55 | 2023-2025 | |
| Janssen Biotech, INC. | $221.37 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $142.28 | 2023-2024 | Sotyktu |
| Incyte Corporation | $129.64 | 2022-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $122.56 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Mayne Pharma Commercial LLC | $78.74 | 2023-2024 | |
| Dermavant Sciences, INC. | $66.88 | 2023-2024 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $61.52 | 2025 | Adbry, Anzupgo |
| Mallinckrodt Hospital Products INC. | $60.28 | 2024-2025 | Acthar |
| Almirall LLC | $44.25 | 2024 | Seysara |
| Kerecis Limited | $41.23 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.18 | 2024 | Jublia, Targretin, Duobrii |
| Galderma Laboratories, L.P. | $28.45 | 2025 | Nemluvio |
| Pfizer INC. | $23.45 | 2025 | |
| Organon LLC | $22.97 | 2025 | Vtama |
| Botanix Sb INC | $22.36 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.00 | 2023 | Spevigo |
| Arcutis Biotherapeutics, INC. | $17.00 | 2024 | Zoryve |
| Biofrontera INC. | $15.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanson Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.